Key Takeaways
- • BRIJ Medical, a San Diego-based medical technology company focused on surgical incision management, closed a $5 million financing round, according to the company's announcement.
- • The round was led by the company's Board of Directors, with most of the participation coming from existing investors.
- • The company markets BRIJ-SEAL, a wound closure device providing a 14-day bacterial barrier, and Brijjit, an active tension offloading device that the company says is clinically shown to eliminate up to 100% of incisional tension.
- • BRIJ Medical says its products are used by plastic and orthopedic surgeons across the U.S. and Canada.
Summary
BRIJ Medical, a medical technology company based in San Diego, California, announced that it has closed a $5 million financing round. The company said the round was led by its Board of Directors, with most of the capital coming from existing investors. The source does not disclose a valuation or the names of individual investors.
The company positions itself in incision management, describing its approach as active tension offloading combined with advanced incision protection. Its portfolio is organized around three stages of care that it describes as covering, protecting, and reinforcing incisions, with the stated goal of supporting surgeons from closure through recovery.
Two products are highlighted. BRIJ-SEAL is an advanced wound closure device that provides a 14-day bacterial barrier. Brijjit is an active tension offloading device that the company says has been clinically shown to eliminate up to 100% of incisional tension. The announcement does not include the underlying clinical study details.
According to the company, BRIJ Medical is trusted by plastic and orthopedic surgeons across the U.S. and Canada. The financing is a private, company-reported round and the announcement does not indicate its intended use of proceeds.
The company positions itself in incision management, describing its approach as active tension offloading combined with advanced incision protection. Its portfolio is organized around three stages of care that it describes as covering, protecting, and reinforcing incisions, with the stated goal of supporting surgeons from closure through recovery.
Two products are highlighted. BRIJ-SEAL is an advanced wound closure device that provides a 14-day bacterial barrier. Brijjit is an active tension offloading device that the company says has been clinically shown to eliminate up to 100% of incisional tension. The announcement does not include the underlying clinical study details.
According to the company, BRIJ Medical is trusted by plastic and orthopedic surgeons across the U.S. and Canada. The financing is a private, company-reported round and the announcement does not indicate its intended use of proceeds.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.